Orihinal doing business as Tolerion, Inc. and organzied around vaccines to treat autoimmune diseases, in late 2002, the firm was renamed Bayhill Therapeutics, Inc. shifting its focus to autoimmune and metabolic diseases. The firm fell victim to the 2008 recession when management attempted an IPO but had to withdraw. At it height, Bayhill Thereapeutics was at the forefront of developing novel and targeted treatment candidates for autoimmune diseases. Leveraging its proprietary therapeutic BHT-DNA⢠platform, the Companyâs product candidates were designed to restore a patientâs immune system âtoleranceâ to self antigens to its normal state by selectively eliminating specific, harmful immune responses while leaving the rest of the immune system intact. Through a targeted and selective approach, Bayhillâs product candidates had the potential to deliver superior efficacy, safety and tolerability relative to current therapies. Though it was later recorded that the firm was winding down its operations but that assets were acquired by a reincarnation, it is not apparent whether th
